Barclays’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-935
| Closed | -$11K | – | 4962 |
|
|
2022
Q1 | $11K | Sell |
935
-6,053
| -87% | -$71.2K | ﹤0.01% | 4475 |
|
|
2021
Q4 | $228K | Buy |
6,988
+2,502
| +56% | +$81.6K | ﹤0.01% | 2791 |
|
|
2021
Q3 | $200K | Sell |
4,486
-1,390
| -24% | -$62K | ﹤0.01% | 2983 |
|
|
2021
Q2 | $320K | Sell |
5,876
-1,828
| -24% | -$99.6K | ﹤0.01% | 2689 |
|
|
2021
Q1 | $577K | Buy |
7,704
+6,330
| +461% | +$474K | ﹤0.01% | 2586 |
|
|
2020
Q4 | $150K | Sell |
1,374
-531
| -28% | -$58K | ﹤0.01% | 2834 |
|
|
2020
Q3 | $168K | Sell |
1,905
-383
| -17% | -$33.8K | ﹤0.01% | 2815 |
|
|
2020
Q2 | $244K | Buy |
2,288
+1,139
| +99% | +$121K | ﹤0.01% | 2705 |
|
|
2020
Q1 | $68K | Sell |
1,149
-2,408
| -68% | -$143K | ﹤0.01% | 2969 |
|
|
2019
Q4 | $245K | Buy |
3,557
+1,768
| +99% | +$122K | ﹤0.01% | 3079 |
|
|
2019
Q3 | $185K | Sell |
1,789
-446
| -20% | -$46.1K | ﹤0.01% | 3101 |
|
|
2019
Q2 | $207K | Buy |
2,235
+1,490
| +200% | +$138K | ﹤0.01% | 3178 |
|
|
2019
Q1 | $68K | Buy |
745
+452
| +154% | +$41.3K | ﹤0.01% | 3526 |
|
|
2018
Q4 | $17K | Sell |
293
-964
| -77% | -$55.9K | ﹤0.01% | 3432 |
|
|
2018
Q3 | $150K | Buy |
1,257
+1,078
| +602% | +$129K | ﹤0.01% | 3209 |
|
|
2018
Q2 | $18K | Sell |
179
-142
| -44% | -$14.3K | ﹤0.01% | 3687 |
|
|
2018
Q1 | $41K | Buy |
321
+123
| +62% | +$15.7K | ﹤0.01% | 3584 |
|
|
2017
Q4 | $19K | Buy |
198
+159
| +408% | +$15.3K | ﹤0.01% | 3717 |
|
|
2017
Q3 | $5K | Buy |
39
+38
| +3,800% | +$4.87K | ﹤0.01% | 3667 |
|
|
2017
Q2 | $0 | Sell |
1
-1
| -50% | – | ﹤0.01% | 4117 |
|
|
2017
Q1 | $0 | Sell |
2
-1
| -33% | – | ﹤0.01% | 4180 |
|
|
2016
Q4 | $0 | Sell |
3
-34
| -92% | – | ﹤0.01% | 4025 |
|
|
2016
Q3 | $5K | Buy |
+37
| New | +$5K | ﹤0.01% | 3429 |
|